Skip to main content
SpringerLink
Log in

Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Managing low-density lipoprotein (LDL) is an integral part of clinical practice. What remains controversial is whether we are using the best measure of LDL quantity for this purpose. Historically, the cholesterol content of LDL particles (LDLC) has been used to express LDL quantity. However, because of variability in the cholesterol carried in LDL particles, frequent disagreement occurs between LDLC and particle measures of LDL quantity, including apolipoprotein B-100 (apo B) or nuclear magnetic resonance (NMR) LDL particle number (LDL-P). Studies consistently demonstrate apo B and LDL-P are superior predictors of coronary heart disease (CHD) risk and superior indicators of low CHD risk on lipid-lowering therapy. Recent recommendations advocate that, in addition to LDLC and non-high-density lipoprotein cholesterol, apo B (or NMR LDL-P) be used as a target of therapy. This article reviews the rationale supporting these recommendations and provides a model for integrating LDL particle measures in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Nielsen L: Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 1996, 123:1–15.

    Article  CAS  PubMed  Google Scholar 

  2. Tabas I, Williams KJ, Boren J: Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832–1844.

    Article  CAS  PubMed  Google Scholar 

  3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report [no authors listed]. Circulation 2002, 106:3143–3421.

  4. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  5. Hayward RA, Hofer TP, Vijan S: Narrative Review: Lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 2006, 145:520–530.

    PubMed  Google Scholar 

  6. Sniderman AD, Furberg CD, Keech A, et al.: Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003, 361:777–780.

    Article  CAS  PubMed  Google Scholar 

  7. Barter PJ, Ballantyne CM, Carmena R, et al.: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006, 259:247–258.

    Article  CAS  PubMed  Google Scholar 

  8. Gotto AM Jr, Whitney E, Stein EA, et al.: Relation between baseline and on-treatment Lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101:477–484.

    CAS  PubMed  Google Scholar 

  9. Simes RJ, Marschner IC, Hunt D, et al.: Relationship between lipid levels and clinical outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002, 105:1162–1169.

    Article  CAS  PubMed  Google Scholar 

  10. van Lennep JE, Westerveld HT, van Lennep HW, et al.: Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000, 20:2408–2413.

    PubMed  Google Scholar 

  11. Sniderman A, Vu H, Cianflone K: Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis 1991, 89:109–116.

    Article  CAS  PubMed  Google Scholar 

  12. Garvey WT, Kwon S, Zheng D, et al.: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453–462.

    Article  CAS  PubMed  Google Scholar 

  13. Jeyarajah EJ, Cromwell WC, Otvos JD: Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006, 26:847–870.

    Article  PubMed  Google Scholar 

  14. Otvos JD, Jeyarajah EJ, Cromwell WC: Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 90:22i–29i.

    Article  CAS  PubMed  Google Scholar 

  15. Cromwell WC, Otvos JD: Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol 2006, 98:1599–1602.

    Article  CAS  PubMed  Google Scholar 

  16. Cromwell WC, Otvos JD, Keyes MJ, et al.: LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: implications for LDL management. J Clin Lipidol 2007, 1:583–592.

    Article  PubMed  Google Scholar 

  17. Sniderman AD: Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. J Clin Lipidol 2008, 2:36–42.

    Article  Google Scholar 

  18. Cremer P, Nagel D, Mann H, et al.: Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997, 129:221–230.

    Article  CAS  PubMed  Google Scholar 

  19. Walldius G, Jungner I, Holme I, et al.: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026–2033.

    Article  CAS  PubMed  Google Scholar 

  20. Simons LA, Simons J, Friedlander Y, McCallum J: Risk factors for acute myocardial infarction in the elderly (the Dubbo study). Am J Cardiol 2002, 89:69–72.

    Article  PubMed  Google Scholar 

  21. Talmud PJ, Hawe E, Miller GJ, Humphries SE: Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002, 22:1918–1923.

    Article  CAS  PubMed  Google Scholar 

  22. Jiang R, Schulze MB, Li T, et al.: Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004, 27:1991–1997.

    Article  CAS  PubMed  Google Scholar 

  23. Shai I, Rimm EB, Hankinson SE, et al.: Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004, 110:2824–2830.

    Article  PubMed  Google Scholar 

  24. Pischon T, Girman CJ, Sacks FM, et al.: Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005, 112:3375–3383.

    Article  CAS  PubMed  Google Scholar 

  25. Ridker PM, Rifai N, Cook NR, et al.: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294:326–333.

    Article  CAS  PubMed  Google Scholar 

  26. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A: Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:661–670.

    Article  CAS  PubMed  Google Scholar 

  27. Ingelsson E, Schaefer EJ, Contois JH, et al.: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776–785.

    Article  CAS  PubMed  Google Scholar 

  28. Blake GJ, Otvos JD, Rifai N, et al.: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002, 106:1930–1937.

    Article  CAS  PubMed  Google Scholar 

  29. Kuller L, Arnold A, Tracy R, et al.: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002, 22:1175–1180.

    Article  CAS  PubMed  Google Scholar 

  30. El Harchaoui K, van der Steeg WA, Stroes ES, et al.: Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 49:547–553.

    Article  PubMed  Google Scholar 

  31. Mora S, Szklo M, Otvos JD, et al.: LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007, 192:211–217.

    Article  CAS  PubMed  Google Scholar 

  32. Mora S, Otvos JD, Rifai N, et al.: Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931–919.

    Article  CAS  PubMed  Google Scholar 

  33. Ruotolo G, Ericsson C-Go, Tettamanti C, et al.: Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998, 32:1648–1656.

    Article  CAS  PubMed  Google Scholar 

  34. Vakkilainen J, Steiner G, Ansquer JC, et al.: Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003, 107:1733–1737.

    Article  PubMed  Google Scholar 

  35. Rosenson RS, Otvos JD, Freedman DS: Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002, 90:89–94.

    Article  CAS  PubMed  Google Scholar 

  36. Otvos JD, Collins D, Freedman DS, et al.: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556–1563.

    Article  CAS  PubMed  Google Scholar 

  37. Genest J, Frohlich J, Fodor G, McPherson R: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003, 169:921–924.

    PubMed  Google Scholar 

  38. Brunzell JD, Davidson M, Furberg CD, et al.: Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51:1512–1524.

    Article  PubMed  Google Scholar 

  39. Contois JH, McConnell JP, Sethi AA, et al.: Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009, 55:407–419.

    Article  CAS  PubMed  Google Scholar 

  40. Kathiresan S, Otvos JD, Sullivan LM, et al.: Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006, 113:20–29.

    Article  CAS  PubMed  Google Scholar 

  41. Sniderman AD, St-Pierre AC, Cantin B, et al.: Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003, 91:1173–1177.

    Article  CAS  PubMed  Google Scholar 

  42. Berneis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002, 43:1363–1379.

    Article  Google Scholar 

  43. Kim BJ, Hwang ST, Sung KC, et al.: Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem 2005, 51:2257–2263.

    Article  CAS  PubMed  Google Scholar 

  44. Stein EA, Sniderman A, Laskarzewski P: Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 2005, 96:36K–43K.

    Article  CAS  PubMed  Google Scholar 

  45. Sniderman AD, Dagenais GR, Cantin B, et al.: High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol. Am J Cardiol 2001, 87:792–793.

    Article  CAS  PubMed  Google Scholar 

  46. Otvos JD: Our own inconvenient truth: LDL cholesterol is a flawed measure of LDL. Time to acknowledge the problem and its clinical implications. The Fats of Life 2009, 23:16–20. http://www.aacc.org/SiteCollectionDocuments/Master%20Newsletter/Lipids_Newsletter_Archives/Fats-LifeSummer2009.pdf.

    Google Scholar 

  47. Cromwell WC, Bays HE, Toth PP: Lipoprotein subfraction analysis using nuclear magnetic resonance spectroscopy. In Markers in Cardiology: A Case-Oriented Approach. Edited by Adams JE, Apple F, Jaffe AS. London: Blackstone Press; 2007:217–250.

    Chapter  Google Scholar 

  48. Maki KC, McKenney JM, Reeves MS, et al.: Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 2008, 102:429–433.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Atherosclerosis and Lipoprotein Disorders, Presbyterian Cardiovascular Institute, 125 Baldwin Avenue, Suite 200, Charlotte, NC, 28204, USA

    William C. Cromwell

Authors
  1. William C. Cromwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas A. Barringer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William C. Cromwell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cromwell, W.C., Barringer, T.A. Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease. Curr Cardiol Rep 11, 468–475 (2009). https://doi.org/10.1007/s11886-009-0067-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-009-0067-z

Keywords

Search

Navigation